Earnings Feed
Start Free
Dianthus Therapeutics, Inc. /DE/·4

Apr 1, 5:26 PM ET

Savitz Ryan 4

4 · Dianthus Therapeutics, Inc. /DE/ · Filed Apr 1, 2026

Research Summary

AI-generated summary of this filing

Updated

Dianthus (DNTH) EVP/CFO Savitz Exercises Options, Sells 114K Shares

What Happened

  • Ryan Savitz, EVP, Chief Financial & Business Officer of Dianthus Therapeutics (DNTH), exercised stock options for a total of 114,367 shares (74,367 shares at $8.44 and 40,000 shares at $17.88) on 2026-03-31, paying about $1.34M in exercise costs.
  • The same 114,367 shares were sold in multiple open-market transactions on 2026-03-31 for aggregate gross proceeds of approximately $9.49M (weighted sales prices across tranches). Net proceeds after the exercise costs were roughly $8.15M. This sequence (exercise then sale) is effectively a cashless exercise and sale rather than an outright purchase for long-term holding.

Key Details

  • Transaction date: March 31, 2026.
  • Options exercised: 74,367 shares @ $8.44 and 40,000 shares @ $17.88 (total exercise cost ≈ $1,342,857).
  • Shares sold: 114,367 shares in multiple trades for total proceeds ≈ $9,492,595 (sales prices ranged roughly $77.74 to $85.97 across trades).
  • Net cash (proceeds minus exercise cost): ≈ $8.15M (before taxes/fees).
  • Footnotes: Sales were effected pursuant to a Rule 10b5‑1 trading plan adopted Dec 30, 2025 (F1). Vesting schedules for the option awards are noted in the filing (F10, F11). Multiple weighted-average price ranges are disclosed for different sale tranches (F2–F9).
  • Shares owned after the transactions: not specified in the provided excerpt of the filing.
  • Timeliness: Form 4 was filed on Apr 1, 2026 covering trades on Mar 31, 2026 — appears timely (no late‑filing flag noted).

Context

  • These were option exercises (transaction code M) followed by sales (S). When exercised shares are immediately sold, it is commonly referred to as a cashless exercise and does not necessarily indicate a long‑term buy signal.
  • The trades were executed under a pre-established 10b5‑1 plan, which typically means the sales were scheduled in advance and reduce the likelihood the trades were based on nonpublic information.
  • The filing is factual; it does not disclose the insider’s motivation or tax strategy.

Insider Transaction Report

Form 4
Period: 2026-03-31
Dianthus Therapeutics, Inc. /DE/DNTH
Savitz Ryan
EVP, CFO & CBO
Transactions
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-03-31$8.44/sh+74,367$627,657→ 74,367 total
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-03-31$17.88/sh+40,000$715,200→ 114,367 total
  • Sale

    Common Stock

    [F1][F2]
    2026-03-31$78.33/sh−1,390$108,879→ 112,977 total
  • Sale

    Common Stock

    [F1][F3]
    2026-03-31$78.86/sh−21,825$1,721,120→ 91,152 total
  • Sale

    Common Stock

    [F1][F4]
    2026-03-31$80.25/sh−1,485$119,171→ 89,667 total
  • Sale

    Common Stock

    [F1][F5]
    2026-03-31$81.36/sh−800$65,088→ 88,867 total
  • Sale

    Common Stock

    [F1][F6]
    2026-03-31$82.84/sh−2,366$195,999→ 86,501 total
  • Sale

    Common Stock

    [F1][F7]
    2026-03-31$83.90/sh−59,800$5,017,220→ 26,701 total
  • Sale

    Common Stock

    [F1][F8]
    2026-03-31$84.57/sh−19,469$1,646,493→ 7,232 total
  • Sale

    Common Stock

    [F1][F9]
    2026-03-31$85.54/sh−7,232$618,625→ 0 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F1][F10]
    2026-03-31−74,367→ 10,399 total
    Exercise: $8.44Exp: 2032-06-06→ Common Stock (74,367 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F1][F11]
    2026-03-31−40,000→ 80,000 total
    Exercise: $17.88Exp: 2034-01-23→ Common Stock (40,000 underlying)
Footnotes (11)
  • [F1]The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2025.
  • [F10]The shares of common stock underlying this stock option award vested as to 25% of the shares on June 2, 2023, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
  • [F11]The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
  • [F2]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $77.74 to $78.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
  • [F3]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $78.74 to $79.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
  • [F4]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $80.11 to $81.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
  • [F5]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $81.15 to $81.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
  • [F6]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.25 to $83.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
  • [F7]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $83.25 to $84.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
  • [F8]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $84.25 to $85.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
  • [F9]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.25 to $85.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
Signature
/s/ Adam Veness, as attorney-in-fact for Ryan Savitz|2026-04-01

Documents

1 file
  • 4
    ownership.xmlPrimary

    4